meta
|
evidence
oncology
Living systematic review and meta-analysis
breast cancer - HER2-positive
es-BC - HER2 positive - (neo)adjuvant (NA)
5
la/mBC - HER2 positive
la/mBC - HER2 positive - (neo)adjuvant (NA)
la/mBC - HER2 positive - 1st Line (L1)
5
la/mBC - HER2 positive - 2nd Line (L2)
13
All treatments
antibody–drug conjugate
trastuzumab emtansine
trastuzumab emtasine plus endocrine therapy
chemotherapy
non platinum-based chemotherapy
taxanes
paclitaxel
paclitaxel followed by doxorubicin plus cyclophosphamide
HER inhibitor
HER2 inhibitor
pertuzumab based treatment
pertuzumab plus trastuzumab
trastuzumab based treatment
trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs taxanes
vs paclitaxel
vs paclitaxel followed by doxorubicin plus cyclophosphamide
vs HER inhibitor
vs HER2 inhibitor
vs pertuzumab based treatment
vs pertuzumab plus trastuzumab
vs trastuzumab based treatment
vs trastuzumab
vs trastuzumab plus endocrine therapy
vs TKI anti HER1/EGFR and HER2/neu
vs lapatinib based treatment
vs lapatinib plus epirubicin and cyclophosphamide followed by docetaxel
vs non active control
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
summary
GRADE
treatment
patients
risk of bias
overview
numeric
bar chart
forest plot
medians
frequency on treatment
benefit risk analysis
Study
study type
RCT
OBS
RCT + OBS
Pathology
T1
T0
Patients
sample sizes
ROB
Results
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open